Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT06940518 trial: what clinicians have said so far
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
- NCT06940518 ↗
- Recruiting
- M.D. Anderson Cancer Center
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT06940518 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06940518 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X |
The trial
ClinicalTrials.gov- Official title
- Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Ivonescimab; Clear Cell Renal Carcinoma
- Interventions
- Ivonescimab
- Arms
- Cohort 2 - (Post-ICB/VEGFTKI) · Experimental
- Cohort 1 - (Post-pure-ICB) · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- Safety and adverse events
- Sponsor
- M.D. Anderson Cancer Center with Strategic Alliance, Summit Therapeutics
- Start
- Jul 2, 2025
- Primary completion
- Jan 19, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06940518 · updated Aug 20, 2026